Compare HOVR & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HOVR | SERA |
|---|---|---|
| Founded | 2013 | 2008 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Precision Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 103.1M | 90.6M |
| IPO Year | N/A | 2021 |
| Metric | HOVR | SERA |
|---|---|---|
| Price | $1.76 | $3.59 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $6.50 | N/A |
| AVG Volume (30 Days) | ★ 932.2K | 42.6K |
| Earning Date | 01-13-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $95,000.00 |
| Revenue This Year | N/A | $19.22 |
| Revenue Next Year | $55.08 | $400.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 1.06 |
| 52 Week Low | $0.35 | $1.37 |
| 52 Week High | $4.18 | $9.13 |
| Indicator | HOVR | SERA |
|---|---|---|
| Relative Strength Index (RSI) | 46.30 | 60.54 |
| Support Level | $1.71 | $2.91 |
| Resistance Level | $1.84 | $3.14 |
| Average True Range (ATR) | 0.14 | 0.26 |
| MACD | 0.06 | 0.04 |
| Stochastic Oscillator | 60.00 | 79.55 |
New Horizon Aircraft Ltd is an aerospace Original Equipment Manufacturer that is designing and building a next-generation hybrid electric vertical take-off and landing aircraft for the regional air mobility market. Its aircraft will offer a more efficient way to move people and goods at a regional scale, help to connect remote communities, and advance its ability to deal with an increasing number of climate-related natural disasters such as wildfires, floods, and droughts. The company aims to deliver a hybrid electric 7-seat aircraft, called the Cavorite X7, that can take off and land vertically like and helicopter.
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.